Browse Category

NASDAQ:FEMY News 16 October 2025 - 3 November 2025

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Company Overview – Innovating in Women’s Health Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick (a female inventor-entrepreneur), Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologies femasys.com gurufocus.com. The company’s mission is to provide women with minimally invasive, office-based alternatives that improve patient care and reduce costs, in areas ranging from infertility to contraception and cancer diagnostics femasys.com gurufocus.com. Safety and accessibility are emphasized – Femasys notes that advances in female reproductive health are “long overdue,” and its products
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 (+52%) before settling at $0.745 (+35%) by the close finance.yahoo.com. This explosive move came amid unusually heavy volume (tens of millions of shares traded, versus ~7 million on a typical day) stockinvest.us, indicating
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination globenewswire.com stocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery ir.femasys.com ir.femasys.com. This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected
Go toTop